MX2023005581A - Glucoformas de fab ricas en manosa. - Google Patents

Glucoformas de fab ricas en manosa.

Info

Publication number
MX2023005581A
MX2023005581A MX2023005581A MX2023005581A MX2023005581A MX 2023005581 A MX2023005581 A MX 2023005581A MX 2023005581 A MX2023005581 A MX 2023005581A MX 2023005581 A MX2023005581 A MX 2023005581A MX 2023005581 A MX2023005581 A MX 2023005581A
Authority
MX
Mexico
Prior art keywords
high mannose
fab
glycoforms
fab high
mannose glycoforms
Prior art date
Application number
MX2023005581A
Other languages
English (en)
Inventor
Wilma Lau
Roland Staack
Wolfgang Richter
Klaus Joeris
Neslihan Oezden
Britta Schmidt
Carsten Hofmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2023005581A publication Critical patent/MX2023005581A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a patrones de glucosilación en la porción Fab de un anticuerpo monoclonal y procedimientos para la regulación durante el cultivo de un microorganismo que expresa un anticuerpo monoclonal con contenido regulado de glucoformas de Fab ricas en manosa.
MX2023005581A 2020-11-16 2021-11-04 Glucoformas de fab ricas en manosa. MX2023005581A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207804 2020-11-16
PCT/EP2021/080692 WO2022101088A1 (en) 2020-11-16 2021-11-04 Fab high mannose glycoforms

Publications (1)

Publication Number Publication Date
MX2023005581A true MX2023005581A (es) 2023-05-29

Family

ID=73452078

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005581A MX2023005581A (es) 2020-11-16 2021-11-04 Glucoformas de fab ricas en manosa.

Country Status (13)

Country Link
US (1) US20240002483A1 (es)
EP (1) EP4244248A1 (es)
JP (1) JP2023549809A (es)
KR (1) KR20230109674A (es)
CN (1) CN116615231A (es)
AU (1) AU2021376837A1 (es)
CA (1) CA3200954A1 (es)
CL (1) CL2023001371A1 (es)
CR (1) CR20230253A (es)
IL (1) IL302740A (es)
MX (1) MX2023005581A (es)
PE (1) PE20231556A1 (es)
WO (1) WO2022101088A1 (es)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
RS52004B (en) 2005-12-12 2012-04-30 F. Hoffmann-La Roche Ag ANTIBODIES AGAINST AMYLOID BETA WITH GLYCOSILATION IN THE VARIABLE REGION
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
RU2015153109A (ru) 2009-09-16 2019-01-15 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применения
CN105849124B (zh) 2013-12-20 2022-04-12 豪夫迈·罗氏有限公司 双重特异性抗体
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO

Also Published As

Publication number Publication date
AU2021376837A1 (en) 2023-06-15
CR20230253A (es) 2023-07-26
EP4244248A1 (en) 2023-09-20
CA3200954A1 (en) 2022-05-19
IL302740A (en) 2023-07-01
WO2022101088A1 (en) 2022-05-19
US20240002483A1 (en) 2024-01-04
JP2023549809A (ja) 2023-11-29
PE20231556A1 (es) 2023-10-03
KR20230109674A (ko) 2023-07-20
CL2023001371A1 (es) 2023-12-01
CN116615231A (zh) 2023-08-18

Similar Documents

Publication Publication Date Title
PH12017502429A1 (en) Anti-transferrin receptor antibodies with tailored affinity
MX2022007676A (es) Anticuerpos caninizados biespecificos para tratar dermatitis atopica.
NZ621483A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
WO2010076400A8 (fr) Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome intraoculaire primitif
MX2023000622A (es) Ensayos para combinaciones de dosis fija.
MX2022001260A (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
MX2021012962A (es) Anticuerpo monoclonal que se une especificamente a gitr.
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
NZ595863A (en) Antibodies to egfl7 and methods for their use
MX2023005581A (es) Glucoformas de fab ricas en manosa.
EP4265717A4 (en) MOUSE ANTI-MCR-1/MCR-2 PROTEIN HYBRIDOMA CELL STRAIN, MONOCLONAL ANTIBODY AND USE
BR112021020532A2 (pt) Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
MX2021015842A (es) Polipeptido variante de dihidrodipicolinato reductasa y procedimiento de produccion de l-treonina mediante el uso del mismo.
GEP20247609B (en) Ethod of producing botulinum toxin
MX2021012765A (es) Metodos para tratar el cancer renal con un anticuerpo anti-psma/cd3.
ATE348842T1 (de) Anti-pilyrosporum ovale igy und dessen verwendung
MX2023003086A (es) Métodos para tratar el mieloma múltiple.
WO2018195457A3 (en) Routes and schedules for treating multiple sclerosis with anti-cd52 antibodies
AR119866A1 (es) Desarrollo de una plataforma de hibridoma eficaz para descubrimiento de anticuerpos terapéuticos
CA3199006A1 (en) Anti-cd25 antibodies
MY195400A (en) Microorganism Having Enhanced L-Threonine Producing Ability and Method for Producing Threonine using the same
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
MX2021009690A (es) Anticuerpo anti-bag2 y metodos de tratamiento del cancer.
EP3998280A4 (en) HYBRIDOME AND METHOD FOR PRODUCTION, MONOCLONAL ANTIBODY AND METHOD FOR PRODUCTION
MX2022012915A (es) Anticuerpo anti-ox40 y usos del mismo.